Atellica CH Microalbumin (Siemens) - Performance Claim Issue (2024)
Hazard assessment based on recall description.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Atellica CH Microalbumin_2 (ALB_2)-For in vitro diagnostic use in the quantitative measurement of microalbumin in human urine on ADVIA Chemistry systems/ Atellica CH and Atellica CI Analyzers
Brand
Siemens Healthcare Diagnostics, Inc.
Lot Codes / Batch Numbers
UDI-DI: 00630414596310 Lot Numbers: 232033, 232128, 232137, 232146, 232147, 242149, 242150, 242365
Products Sold
UDI-DI: 00630414596310 Lot Numbers: 232033, 232128, 232137, 232146, 232147, 242149, 242150, 242365
Siemens Healthcare Diagnostics, Inc. is recalling Atellica CH Microalbumin_2 (ALB_2)-For in vitro diagnostic use in the quantitative measurement of mi due to Atellica CH Microalbumin_2 (ALB_2) and the ADVIA Chemistry Microalbumin_2 (ALB_2) are not meeting the High-Dose Hook Effect claim/Prozone Effect claim. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Atellica CH Microalbumin_2 (ALB_2) and the ADVIA Chemistry Microalbumin_2 (ALB_2) are not meeting the High-Dose Hook Effect claim/Prozone Effect claim as stated in the Instructions for Use (IFU) on the Atellica CH, Atellica CI Analyzers, ADVIA 1800 Chemistry Systems, ADVIA 2400 Chemistry Systems, and ADVIA Chemistry XPT Systems, may result in erroneously depressed microalbumin patient results.
Recommended Action
Per FDA guidance
Siemens Healthcare issued Urgent Medical Device Corrections (UMDC) to US consignees ACHC24-05.A.US, ACHC24-05.A.US.CHC on 8/15/24 via FedX and Urgent Field Safety Notices (UFSN)to foreign consignees ACHC24-05.A.OUS, ACHC24-05.A.OUS.CHC to affected customers informing them of the issue and the impact to results. ADVIA Chemistry customers are advised that lot 665399 meets the IFU prozone claim. Customers will be instructed to discontinue use of and discard the impacted reagent lots indicated in the letter. Atellica CH customers will be advised that lots 242194, 242195, and 242321 meet the IFU prozone claim. Customers can continue to use the impacted products, with the understanding that patient samples with values above 9,500 mg/dL (95,000 mg/L) can result in falsely depressed results when using the impacted lots. Please retain this letter with your laboratory records and forward this letter to those who may have received this product. Resolution Lot 665399 meets the IFU prozone effect claim. The manufacturing control system has been updated to ensure that there is no impact to future lots. If you have any questions, please contact your Siemens Healthineers Customer Care Center or your local Siemens Healthineers technical support representative.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026